Live Breaking News & Updates on Dave Swalm Chair

Stay updated with breaking news from Dave swalm chair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression and survival

Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression and survival
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Sethp Lerner , Dave Swalm , Clinical Cancer Research , Cancer Research Network , Association Of Molecular Subtypes , Urologic Oncology At Baylor College Of Medicine , Clinical Cancer , Dave Swalm Chair , Urologic Oncology , Baylor College , Cancer Genome Atlas , Molecular Subtypes , Pathologic Response , Muscle Invasive Bladder Cancer ,

Extended lymphadenectomy for locally advanced bladder cancer provides no patient benefit

An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times. ....

United States , Sethp Lerner , Megan Craig , Dave Swalm , Canadian Cancer Society , American Society Of Clinical Oncology , National Cancer Institute , National Institutes Of Health , Cancer Research Network , Urologic Oncology At Baylor College Of Medicine , National Clinical Trials Network , American Society , Clinical Oncology , Dave Swalm Chair , Urologic Oncology , Baylor College , Research Network , National Institutes , Clinical Trials Network , Bladder Cancer , Lymph Node , Clinical Trial , Lymph Nodes ,

Extended lymph node removal does not benefit

An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times. It does, however, increase the risk of adverse events (side effects) and post-surgical death. These primary results from the phase 3 SWOG S1011 clinical trial are being delivered in an oral presentation at the 2023 annual meeting of the American Society of Clinical Oncology in Chicago on June 5 (Abstract 4508). ....

United States , Franciscog Larosa , Ianm Thompson Jr , Ajai Alva , Sumantak Pal , Roberts Svatek , Adams Kibel , Wassim Kassouf , Kamal Pohar , Aashish Kamat , Sethp Lerner , Theresam Koppie , Arthuri Sagalowsky , Siamak Daneshmand , Catherine Tangen , Anne Schuckman , Dave Swalm , City Of Hope Medical Center , National Institutes Of Health , University Of Texas Health San Antonio , Stanford University , Md Anderson Cancer Center , Mcgill University Health Center , American Society Of Clinical Oncology , Ohio State University , Community Oncology Research Program ,